journal article
oaidoi:10.1016/j.bmcl.2014.06.038

Recent progress in sodium channel modulators for pain

Authors
Publication date
15 August 2014
Publisher
The Authors. Published by Elsevier Ltd.
Doi

    Abstract

    AbstractVoltage-gated sodium channels (Navs) are an important family of transmembrane ion channel proteins and Nav drug discovery is an exciting field. Pharmaceutical investment in Navs for pain therapeutics has expanded exponentially due to genetic data such as SCN10A mutations and an improved ability to establish an effective screen sequence for example IonWorks Barracuda®, Synchropatch® and Qube®. Moreover, emerging clinical data (AZD-3161, XEN402, CNV1014802, PF-05089771, PF-04531083) combined with recent breakthroughs in Nav structural biology pave the way for a future of fruitful prospective Nav drug discovery

    Similar works

    Full text

    thumbnail-image

    Elsevier - Publisher Connector

    redirect
    oaidoi:10.1016/j.bmcl.2014.06.038
    Last time updated on 06/05/2017

    This paper was published in Elsevier - Publisher Connector .

    Having an issue?

    Is data on this page outdated, violates copyrights or anything else? Report the problem now and we will take corresponding actions after reviewing your request.